Bausch + Lomb Bausch + Lomb
Bausch + Lomb

Join us in Los Angeles

Lights Camera Cataracts: A New Look at Dry Eye and IOL Technology

Friday, April 25, 2025 | 6:45pm - 9:00pm PDT

The Clive Davis Theater at LA Live
800 W Olympic Blvd, Los Angeles, CA 90015

Join Darrell White, MD, as he hosts an expert panel featuring Sheri Rowen, MD; I. Paul Singh, MD; and special guest Julie Bowen. In this discussion, the panel will explore surgical preparation and IOL decision-making strategies with a focus on how dry eye management affects cataract surgery outcomes. Then Julie Bowen will share her personal journey as a dry eye patient, providing valuable insight into the real-world challenges of living with this condition. Don't miss this opportunity to hear from leading specialists and gain a first hand patient perspective on effective dry eye management.

Miebo xiidra anVista ENVY

Faculty:

Darrell White, MD

Talk Show Host

Darrell White, MD

Sheri Rowen, MD

Panelist

Sheri Rowen, MD

Paul Singh, MD

Panelist

Paul Singh, MD

Julie Bowen

Actress and Dry Eye Patient

Julie Bowen

Indication and Important Safety Information for MIEBO

INDICATION

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information for MIEBO.

Indications and Important Safety Information for Xiidra®

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information

Register